SOL-804: Prostate cancer treatment
-
Bukwang’s formulation-focused subsidiary, Dyna Therapeutics (KR) has entered exclusive option agreement with Solural Pharm to license patented SOL-804 for WW right
-
SOL-804: new formulation of currently available drug with Lymphatic Targeting Technology
- Eliminates food effect
- Better safety profile due to reduced dosing level
-
Preclinical in 2017
